Independent Physician Surveys Show If Approved, MF101 Could Become First-Line Treatment For Menopause Symptoms

Bionovo, Inc. (Nasdaq: BNVI) announced results from two independent physician surveys which showed MF101 could become first-line treatment for menopausal vasomotor symptoms (hot flashes). In both qualitative and quantitative studies, 124 physicians board certified in internal medicine or obstetrics and gynecology specializing in the treatment of menopause reported MF101, if approved, would be their drug of choice for the treatment of hot flashes.

More: continued here

Filed under: Endocrinology on March 15th, 2008